Viatris (formerly Mylan) has become the first drugmaker to win full FDA approval for a generic version of AstraZeneca's top-selling respiratory drug Symbicort, although launch plans remain uncertain ...

Commercial rights cover Greater China with first launch slated Q2 2026, handing pharma blogs CXG87 keywords and revenue forecast. HANGZHOU, China, Oct. 9, 2025 /PRNewswire/ -- Chance Pharmaceuticals ( ...

HANGZHOU, China, Oct. 9, 2025 /PRNewswire/ -- Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative ...

During the third quarter, Iconovo carried out a reorganization to focus on the three largest near-term opportunities: ICOpre, ICOres, and the development of an intranasal version of semaglutide.

New Delhi: AstraZeneca Pharma India Limited has received a show cause notice from the National Pharmaceutical Pricing Authority (NPPA), which has raised a demand of Rs 60.49 crore plus interest over ...

AstraZeneca Pharma India Ltd has announced that it received a Show Cause Notice from the National Pharmaceutical Pricing Authority (NPPA), Department of Pharmaceuticals, on September 11, 2025, ...

Iconovo AB (publ), which develops complete inhalation products for a global market, today announced that the European Patent Office (EPO) intends to approve the company's application for a patent for ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Bangalore: AstraZeneca Pharma India Limited and Mankind Pharma Limited have entered into an agreement for exclusive distribution of AstraZeneca’s budesonide and formoterol fumarate dihydrate (inhaled ...